Pilot study of flesinoxan, a 5‐HT1A agonist, in major depression: Effects on sleep REM latency and body temperature

  title={Pilot study of flesinoxan, a 5‐HT1A agonist, in major depression: Effects on sleep REM latency and body temperature},
  author={Marc Ansseau and William Pitchot and Antonio Gonzalez Moreno and Jacques Wauthy and Patrick Papart},
  journal={Human Psychopharmacology: Clinical and Experimental},
Flesinoxan is a highly potent and selective 5‐HT1A full agonist, active in several models of depression. In this pilot open study, flesinoxan (4 mg/d) was administered orally for 4 weeks in 16 major depressive, mostly treatment‐resistant inpatients exhibiting a score of at least 19 on the Hamilton depression sale. Weekly ratings included Hamilton depression scale, Montgomery and Asberg depression scale (MADRS), and Clinical Global Impressions (CGI). Results showed considerable improvement in… 

5‐HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response

It is concluded that selective targeting of 5‐HT receptors may lead to a faster acting and more efficient antidepressant response.

Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

In agreement with pharmacological studies, presynaptic and postsynaptic 5- HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT 1A-Rs are also involved.

5‐HT1A Receptor Agonist Flesinoxan Enhances Fos Immunoreactivity in Rat Central Amygdala, Bed Nucleus of the Stria Terminalis and Hypothalamus

Investigation of immunoreactivity for the immediate early gene protein product Fos (Fos‐ir) in rat brains 1 h after flesinoxan treatment suggests the involvement of corticotropin‐releasing hormone (CRH) or vasopressin in the hypothalamus, which suggests its activating effects on the HPA axis via CRH neurons in the PVN.



Ipsapirone: evidence for efficacy in depression.

The efficacy results for patients with the diagnosis of neurotic depression were similar for the intent-to-treat population, and safety and tolerability were evaluated for all study patients independent of diagnosis.

Buspirone in depressed outpatients: a controlled study.

Buspirone was found to be safe and well-tolerated by patients with major depression and concomitant anxiety at doses of up to 90 mg/day.

REM latency: a psychobiologic marker for primary depressive disease.

  • D. Kupfer
  • Psychology, Medicine
    Biological psychiatry
  • 1976
It is indicated that short REM latency is found in virtually all primary depressive illness and is absent in secondary depression, and it is argued that the phenomenon is independent of age, drug effect and changes in other sleep parameters.

Explorative single‐blind study on the sedative and hypnotic effects of buspirone in anxiety patients

It is concluded that buspirone does not have a sedative or hypnotic effect in anxiety patients and sleep structure was minimal and of no clinical consequence.

A New Depression Scale Designed to be Sensitive to Change

The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.

REM latency in depression: is there one best definition?

The range of sensitivities yielded by different definitions was narrower and not clearly affected by sleep-onset criterion or exclusion/inclusion of wakefulness between sleep onset and first REM period, and the shorter REM latencies in both outpatients and inpatients were associated with a later time of NREM sleep onset than in controls.

Sleep and treatment prediction in endogenous depression.

In 34 drug-free patients with primary endogenous depression treated with amitriptyline, the application of EEG-monitored sleep criteria alone was more significant than clinical status alone in the prediction of clinical response.

Antidepressants and EEG sleep: search for specificity.

The EEG sleep profile in de-pressed patients improves the diagnostic classification of affective states, offers an objective set of indicators in assessing the severity of illness, and provides an aid to the choice and length of treatment.


  • M. Hamilton
  • Psychology, Medicine
    Journal of neurology, neurosurgery, and psychiatry
  • 1960
The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information.